Working… Menu

A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02492789
Recruitment Status : Completed
First Posted : July 9, 2015
Last Update Posted : September 30, 2019
Information provided by (Responsible Party):
Atridia Pty Ltd.

Brief Summary:
This is an open-label, multicenter, non-randomized, dose escalation and tumor-expansion phase I trial to evaluate safety and tolerability of INCSHR01210 in patients with advanced solid tumors. The trial will enroll subjects with advanced solid tumor who have failed current standard anti-tumor therapies.

Condition or disease Intervention/treatment Phase
Solid Tumors and Hematologic Malignancy Biological: INCSHR01210 injection Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 49 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Multicenter, Nonrandomized, Dose-Escalation and Tumor-Expansion Phase 1 Study to Evaluate the Safety and Tolerability of INCSHR01210 (Formerly SHR-1210) in Subjects With Advanced Solid Tumors
Study Start Date : September 1, 2015
Actual Primary Completion Date : March 1, 2019
Actual Study Completion Date : July 5, 2019

Arm Intervention/treatment
Experimental: INCSHR01210
3 dose levels are designed in this study.3 to 6 patients (traditional "3+3" design) will be enrolled in each dose cohort. INCSHR01210 injection at each dose level is administered every 2 weeks (q2w, except in the first cycle).
Biological: INCSHR01210 injection

Part1: INCSHR01210 injection at a dose of 1, 3 or 10 mg/kg is administered every 2 weeks (3+3,q2w, except in the first cycle, in which subjects will be only dosed once on Day 1 for PK samplings and dose limiting toxicity observation). Response is assessed by every 2 cycles (4 weeks each cycle) by using irRECIST.

Part2: Additional patients (200mg dose cohorts will be enrolled in Part 2, depending on the data outcomes in Part 1, to further explore preliminarily clinical benefits of INCSHR01210 as well as the other objectives of the study.

Other Names:
  • SHR-1210
  • HR-301210

Primary Outcome Measures :
  1. Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 15 months ]
    Recommended phase II doses (RP2D) is 200 mg, and the only dose interval to be tested will be once every 4 weeks (Q4W).

Secondary Outcome Measures :
  1. Pharmacokinetics (PK) profile of INCSHR01210 (Tmax) [ Time Frame: Day 1 of cycle 1 ]
  2. Maximum tolerated dose (MTD) of INCSHR01210 [ Time Frame: 6 months ]
  3. Incidence of anti-INCSHR01210 antibody in serum [ Time Frame: 15 months ]
  4. PD-1 receptor occupancy [ Time Frame: 15 months ]
  5. Duration of response [ Time Frame: 15 months ]
  6. Objective response rate [ Time Frame: 15 months ]
  7. Time to progression [ Time Frame: 15 months ]
  8. Pharmacokinetics (PK) profile of INCSHR01210 (Cmax) [ Time Frame: Day 1 of cycle 1 ]
  9. Pharmacokinetics (PK) profile of INCSHR01210 (AUC0-28day) [ Time Frame: Day 28 of cycle 1 ]
  10. Pharmacokinetics (PK) profile of INCSHR01210 (accumulation ratio R) [ Time Frame: Day 28 of each cycle ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female at least 18 years of age;
  • Patients diagnosed with solid tumors histologically or cytologically and documented as advanced or metastatic disease for which there is no known effective anti-tumour treatment (refractory to or relapsed from standard therapies);
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;
  • Life expectancy ≥ 12 weeks;
  • Patients enrolled to Part 2 Expansion Cohorts:

    • must have measurable lesion(s) according to the RECIST v1.1;
    • Cohort A (endometrial carcinoma): Subjects diagnosed with histologically confirmed advanced or metastatic endometrial carcinoma (sarcomas and mesenchymal tumors are excluded). Subjects must have relapsed or be refractory to at least 1 prior standard therapy in the metastatic setting, have been intolerant to standard therapies, or have refused standard therapy. In addition, subjects with disease recurrence within 12 months of completion of adjuvant therapy are eligible.
    • Cohort B (thymic carcinoma): Subjects diagnosed with histologically or cytologically confirmed advanced or metastatic thymic carcinoma based on local guidelines.
    • Cohort C (biliary tract carcinoma): Subjects diagnosed with histologically or cytologically confirmed, advanced or metastatic extrahepatic cholangiocarcinoma (carcinoma of the gallbladder or biliary tree) or carcinoma of the ampulla of Vater. Subjects must have relapsed or be refractory to at least 1 prior standard therapy, have been intolerant to standard therapies, or have refused standard therapy.
    • Cohort D (CUP): Subjects diagnosed with CUP based on ESMO guidelines.
  • Adequate laboratory parameters at screening period as evidenced by:

    • Absolute neutrophil count ≥ 1.5×109/L (1,500/mm3)
    • Platelets ≥100×109/L (100,000/mm3)
    • Hemoglobin ≥ 9.0 g/dL (90 g/L)
    • Albumin levels ≥ 2.8 g/dL
    • Total bilirubin ≤ 1.5×ULN
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5×ULN; for patients with liver metastases, ALT and AST ≤ 5×ULNSerum creatinine ≤ 1.5×ULNAble to understand and sign an informed consent.

Exclusion Criteria:

Subjects who fulfill any of the following criteria at screening will be ineligible for admission:

  • Subjects with any active autoimmune disease or history of autoimmune disease, or history of syndrome that requires systemic steroids or immunosuppressive medications, including but not limited to the following: rheumatoid arthritis, pneumonitis, colitis (inflammatory bowel disease), hepatitis, hypophysitis, nephritis, hyperthyroidism, and hypothyroidism, except for subjects with vitiligo or resolved childhood asthma/atopy. Subjects with the following conditions will not be excluded from this study: asthma that requires intermittent use of bronchodilators, hypothyroidism stable on hormone replacement, vitiligo, Graves' disease, or Hashimoto's disease. Additional exceptions may be made with medical monitor approval.
  • Known history of hypersensitivity to any components of the INCSHR01210 formulation.
  • Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids. Doses > 10 mg/day prednisone or equivalent are prohibited within 2 weeks before study drug administration. Note: corticosteroids used for the purpose of intravenous contrast allergy prophylaxis are allowed.
  • Active CNS metastases (indicated by clinical symptoms, cerebral edema, steroid requirement, or progressive disease). Subjects with brain or meningeal metastases that were previously treated must be clinically stable (magnetic resonance imaging at least 4 weeks apart do not show evidence of new or enlarging metastases) and have discontinued immunosuppressive doses of systemic steroids (> 10 mg/day prednisone or equivalent) for at least 2 weeks before study drug administration.
  • Uncontrolled clinically significant medical condition, including but not limited to the following: (1) congestive heart failure (New York Health Authority Class > 2), (2) unstable angina, (3) myocardial infarction within the past 12 months, or (4) clinically significant supraventricular arrhythmia or ventricular arrhythmia requiring treatment or intervention.
  • Prior systemic chemotherapy (< 6 weeks if chemotherapy including nitrosoureas or mitomycin), radiotherapy, immunotherapy, hormone therapy, surgery or target therapy within 4 weeks before the study drug administration, or any unresolved adverse events > CTCAE Grade 1 (with the exception of any stable chronic toxicities not expected to resolve).
  • Active infection or an unexplained fever > 38.5°C during screening visits or on the first scheduled day of dosing (at the discretion of the investigator, subjects with tumor fever may be enrolled).
  • History of immunodeficiency including seropositivity for human immunodeficiency virus, or other acquired or congenital immune-deficient disease.
  • Any other medical (eg, pulmonary, metabolic, congenital, endocrinal or CNS disease), psychiatric, or social condition deemed by the investigator to be likely to interfere with a subject's rights, safety, welfare, or ability to sign informed consent, cooperate, and participate in the study or would interfere with the interpretation of the results.
  • Investigational therapy administered within 4 weeks before the first dose of INCSHR01210.
  • Evidence of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection or risk of reactivation based on institutional guidelines and tests. Testing may include the following: HBV DNA, HCV RNA, hepatitis B surface antigen, or anti-hepatitis B core antibody.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02492789

Layout table for location information
Australia, Victoria
Austin Hospital/Olivia Newton-John Cancer Research Institute
Heidelberg, Victoria, Australia
Blacktown Hospital
Blacktown, Australia
Chris O'Brien Life House
Camperdown, Australia
Nucleus Network
Melbourne, Australia
Linear Clinical Research Limited
Nedlands, Australia
Sponsors and Collaborators
Atridia Pty Ltd.
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Atridia Pty Ltd. Identifier: NCT02492789    
Other Study ID Numbers: INCSHR1210-101
First Posted: July 9, 2015    Key Record Dates
Last Update Posted: September 30, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by Atridia Pty Ltd.:
solid tumor
PD-1 blockade
Additional relevant MeSH terms:
Layout table for MeSH terms
Hematologic Neoplasms
Neoplasms by Site
Hematologic Diseases